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Introduction: The requirement for the immunoregulatory Mer tyrosine kinase (Mer) for optimal removal of
apoptotic cells prompted us to look at its expression in systemic lupus erythematosus (SLE), in which apoptotic cell
clearance is abnormal. We compared the levels of expression of Mer in normal human subjects and in patients with
SLE.
Methods: We used flow cytometry of isolated peripheral blood mononuclear cells to compare the levels of Mer on
leukocyte subsets. We used a Mer-specific enzyme-linked immunosorbent assay (ELISA) to quantify soluble Mer
(sMer) in plasmas.
Results: Monocytes, CD1c+ myeloid dendritic cells (mDCs), and plasmacytoid dendritic cells (pDCs) from both
normal individuals and from SLE patients expressed Mer. In both normal and SLE patients, the CD14++CD16+
subpopulation of monocytes expressed the highest levels of Mer, with somewhat lower levels on the CD14intCD16+
population. Mer levels on CD1c+ mDCs and pDCs, and sMer levels in blood were increased in SLE patients
compared with controls. In patients, Mer levels on CD14intCD16+, CD14++CD16− monocytes, and CD1c+ dendritic
cells correlated positively with type I interferon (IFN-I) activity detected in blood. In SLE patients treated with
corticosteroids, Mer expression on monocytes correlated with prednisone dose, CD1c+ myeloid dendritic cells in
patients treated with prednisone had higher levels of Mer expression than those in patients not receiving
prednisone.
Conclusions: We found no global defect in Mer expression in lupus blood. In contrast, we observed increased
levels of Mer expression in DC populations, which could represent a response to increased IFN-I in SLE patients.
Enhanced Mer expression induced by corticosteroids may contribute to its beneficial effects in SLE.Introduction
The Tyro3, Axl, and Mer receptors (TAMRs) comprise a
family of receptor tyrosine kinases [1]. They are involved
in the process of apoptotic debris recognition and removal
in normal animals [2,3]. Their extracellular domains con-
tain two N-terminal immunoglobulin-like domains that* Correspondence: philco@temple.edu
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reproduction in any medium, provided the orare essential for binding the C-terminal part of their
ligands, protein S and Gas6. These two ligands have
similar protein-domain structure. The N-terminal Gla
domain of the ligands can bind the phosphatidyl serine
on the surface of apoptotic cells, whereas two C-
terminal laminin G-type receptor domains, comprising
a sex hormone-binding globulin domain, can bind TAMR
expressed on the surface of phagocytic cells. Activation of
TAMR by Gas6 or protein S on the surface of apoptotic
debris facilitates phagocytosis of the apoptotic debris and
triggers an associated suppression of proinflammatoryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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controlling immune responses to antigens exposed on
apoptotic cells.
In gene-expression studies, Mer (named for its expres-
sion in monocytes, endothelium, and the reproductive
system) is the most highly expressed of the TAMR in the
immune system, whereas Axl is expressed at lower levels
in monocytes [10] and also can be expressed in dendritic
cells [9,11,12]. Tyro3, conversely, is widely expressed in
the central nervous system, with little expression in the
immune system [1]. In human peripheral blood, little in-
formation exists about constitutive TAMR expression.
Mer is expressed in a population of pulmonary macro-
phages isolated from bronchoalveolar lavage, and its ex-
pression is increased in smokers [13] Mer expression is
also increased on monocytes and neutrophils in patients
with septic shock [14].
In mice, the TAMRs are implicated in the phagocytosis
of apoptotic debris in the retina, the testis, and the
hematopoietic and immune systems [2]. Activation of
Mer provokes changes in the cytoskeleton of phagocytes,
leading to the ingestion of apoptotic debris [15]. Mer de-
ficiency results in a defective ability to remove apoptotic
cells [3], which leads to a buildup of apoptotic debris.
This accumulation of apoptotic cells and debris may
stimulate autoreactivity [16].
Importantly, Mer expressed in DCs is an important
factor in maintaining peripheral tolerance [7]. Mer defi-
ciency could thus contribute to lack of tolerogenic den-
dritic cells and to excess apoptotic cell-derived antigen
presentation.
A cardinal feature of human systemic lupus erythema-
tosus (SLE) is the presence of autoantibodies against nu-
clear antigens. Because humans with SLE have been
found to have defective clearance of apoptotic cells
[17-20], it has been proposed that the nuclear antigens
contained in such debris may serve as immunogens for
anti-nuclear antibody immune responses [21].
Because clearance of apoptotic debris is impaired in
SLE, we wondered whether TAMR expression might be
diminished in this disorder. In SLE, perturbations in the
levels of TAMR ligands Gas6 and protein S and soluble
TAMR are associated with disease activity [22-25], indi-
cating that TAMR may be involved in disease progres-
sion. To examine the hypothesis that TAMRs are
deficient in patients with lupus, we first tested and iden-
tified antibodies that could reliably detect TAMR. We
were able to identify antibodies that could reliably detect
Mer and Tyro3; however, we were unable to find an
antibody that could specifically recognize Axl. We used
flow cytometry to examine the expression of Mer and
Tyro3 on peripheral blood leukocytes. We found that
Mer was expressed on human monocytes, especially on
the CD14++CD16+ subpopulation, and also on CD1c+myeloid DCs, and at lesser levels on pDCs. When mye-
loid and plasmacytoid dendritic cells from SLE patients
were compared with those from normal healthy subjects,
we found that expression of Mer was significantly in-
creased in lupus patients compared with normal sub-
jects. This increase in expression could result from
inflammatory stimulation, and indeed, Mer expression
correlated with IFN-I activity in patient plasma.
Materials and methods
Subject recruitment
Patients and healthy controls consented to donate blood
in accordance with a protocol approved by the Temple
University Institutional Review Board. Normal subjects
were recruited from students and workers at the Temple
Health Sciences Campus. Only healthy subjects report-
ing no chronic illness or acute infections were recruited.
SLE patients were from the Rheumatology Clinic at
Temple University Hospital. Patients were diagnosed
with lupus and fulfilled at least four American College of
Rheumatology criteria (1997 Revision). The research proto-
col and consent forms were approved by the Temple
University Institutional Review Board.
Flow cytometry
After informed consent was obtained, venous blood was
drawn from patients and normal subjects into EDTA-
containing vacutainers (Becton Dickinson, Franklin
Lakes, NJ). Peripheral blood mononuclear cells (PBMCs)
were purified from blood by using Ficoll/Hypaque sedi-
mentation to remove red blood cells and granulocytes.
Then 0.5 × 106 cells were stained with fluorescent anti-
bodies for analysis with flow cytometry. Antibodies used
in the study and specific for Mer (clone 125518) and
Tyro 3 (clone 96201) were obtained from R&D (Minne-
apolis, MN, USA); Anti–CD1c (clone L161), −CD11c
(clone BU15), −CD14 (clone M5E2), −CD42b (clone
HIP1), −CD56 (clone HCD56), −CD 123 (clone 6H6),
and -FcERI (clone AER-37) were obtained from Biole-
gend, San Diego, CA, USA; Anti-CD4 (clone RPA-T4)
was obtained from eBiosciences (San Diego, CA, USA),
and Anti-CD3 (clone UCHT1), −CD16 (clone 3G8),
−CD19 (clone SJ25C1), and -HLA-DR (clone G46-6),
were obtained from BD Biosciences, San Jose, CA, USA.
PBMCs were blocked by using a mixture of normal
IgG from human and goat (1 mg each per tube). Anti-
body panels were added, and the cells were incubated on
ice. Cells were washed and fixed in 1% paraformaldehyde
for 10 minutes, and washed and resuspended in PBS for
analysis. Leukocyte subpopulations were defined by
using antibodies to CD3, CD14, CD19, and CD56 to de-
lineate T cells, monocytes, and B and NK cells, respect-
ively. Anti-CD42b was used to exclude leukocyte-platelet
aggregates, which are reported to express TAMR. Flow-
Table 1 Healthy normal and SLE patient characteristics
Group 1 Group 2
Demographic Lupus Normal Lupus Normal
Age (years) 37.87 ± 10.23 38.41 ± 13.82 46.1 ± 14.0 40.5 ± 12.4




15 3 19 7
Hispanic 7 0 5 0
Caucasian 0 11 6 5
















C3 low (<90) 6/22 7/29
C4 low (<16) 5/22 8/29
SLEDAI mean ±
StDev
3.17 ± 3.13 5.6 ± 3.4
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ometer (Becton Dickinson, Franklin Lakes, NJ, USA) and
analyzed by using FlowJo software (Treestar, Ashland, OR,
USA). To define subpopulations of monocytes, we used a
five-color strategy including anti-CD16 (clone 3G8, BD
Biosciences), anti-CD14, and anti-MHC II to identify
subsets of monocytes, and collected the data on a
FACSCanto flow cytometer (Becton-Dickinson). To de-
fine dendritic cells, we used a six-color strategy with
anti-CD1c, −CD3, −CD19, −CD123, −HLADR, in addition
to anti-Mer to identify CD1c+ myeloid DCs, the majority
of myeloid dendritic cells. We used antibody-coated beads
to compensate the data; however, we found that the plas-
macytoid dendritic cells CD123-PE.Cy7+ gave values for
PE (Mer) in the negative range by using this compensa-
tion; therefore, we used manual compensation PE-Cy7-PE
to adjust the PE-Cy7hi cell population to match the PE
fluorescence values of the PE-Cy7-negative cells in a cell
sample that contained no Mer-labeled antibody.
sMer ELISA
The total Mer ELISA kit duoset from R&D was used to
quantify Mer in plasmas from lupus patients and normal
controls. Conventional methods were used to carry out
the ELISA. The monoclonal capture antibody at a con-
centration of 1.6 μg/ml was used to coat high-binding
96-well plates. Plates were blocked with 1% BSA.
Plasmas were diluted 1:4 in PBS containing 1% BSA for
use in the assay. The polyclonal biotinylated detection
antibody was used at a concentration of 200 ng/ml.
Horseradish peroxidase conjugated to streptavidin (R&D)
was used with TMB substrate to detect the antigen. The
ELISA could detect the extracellular portion of Mer in a
Mer-Human Fc fusion protein.
Interferon type 1 (IFN-I) activity assay
This assay measures IFN-I activity by using an
interferon-sensitive reporter element linked to an alka-
line phosphatase gene. Hek Blue ISRE-SEAP cells (Invi-
voGen, San Diego, CA, USA) were plated at 50,000 cells
per well in 200 μl media and incubated overnight at 37°C.
The next day, supernatants were removed from cells and
replaced with 100 μl of a 50% plasma/media dilution. Cells
were incubated overnight with plasma at 37°C. Next day,
40 μl of supernatant from every well was added to 160 μl
of AP substrate and allowed to incubate for 20 minutes.
The plate was read at 650-nm absorbance by using a
spectrophotometer.
Statistics
The Welch t test was used for statistical comparison of
TAMRs between SLE patients and normal controls for
data that showed gaussian distribution and unequal vari-
ances. Spearman Rank correlation test was used withdata that showed non-gaussian distribution. Graphpad
Prism (GraphPad Software, Inc., La Jolla, CA) was used
for the comparison and correlative analyses. For all tests,
significance was defined as P < 0.05.
SLE disease activity index (SLEDAI) estimation
The SLEDAI Selena modification was used for scoring
[26]. The score was estimated by examining the patient
chart and the doctor’s comments of the day of the pa-
tient blood draw. The patient was considered to be anti-
double-stranded DNA positive on the day of the visit if
the patient had positive serology in the past.
Results
We recruited a total of 48 lupus patients and 35 healthy
individuals for our study. These subjects were used in
two groups. The first cohort was used to study the ex-
pression of Mer and Tyro3 in leukocyte subpopulations
(Group 1), and the second, to study the expression of
Mer on monocyte subsets and dendritic cell subsets
(Group 2). The clinical characteristics of the groups are
given in Table 1. It should be noted that the control and
lupus cohorts are not well matched for gender and
Hilliard et al. Arthritis Research & Therapy 2014, 16:R76 Page 4 of 15
http://arthritis-research.com/content/16/2/R76ethnicity. We examined the effect of gender on the ex-
pression of Mer, and the results are described later.
Expression of TAMRs on peripheral blood mononuclear
cells of normal individuals
In initial experiments, phycoerythrin-conjugated anti-
Mer and anti-Tyro3 antibodies were identified that gave
positive staining on tumor cell lines known to express
Mer (THP-1) and Tyro3 (K562) (see Additional file 1:
Figure S1). With these antibodies, we examined the ex-
pression of the TAMR on human peripheral blood cells
with multicolor flow cytometry. We included in our
panel of antibodies monoclonal antibodies to recognize
B (CD19), T (CD3), and natural killer (CD56) lympho-
cytes, and monocytes (CD14). These antibodies were
used in combination to identify T, B, NK cells, mono-
cytes with high CD14 expression, and cells expressing
intermediate levels of CD14. Subset population discrim-
ination is shown in Figure 1A. The relative levels of ex-
pression of Mer and Tyro3 on the leukocyte subsets
were examined by using anti-Mer and anti-Tyro3 mono-
clonal antibodies. Highest expression of Mer was observed
on monocytes, with minimal expression on lymphocytes.
(Figure 1B; Additional file 1: Figure S2). We examined one
normal subject at two different time points and another
normal subject at three different time points, and ob-
served some variation in expression over time (Figure 1C).
Our initial antibody panel was designed to examine
the expression of Mer and Tyro3 on the major leukocyte
subsets, and we did not attempt to examine theFigure 1 Flow-cytometric analysis of leukocyte subsets from the perip
identifying leukocyte subsets. (B) Mer expression on the surface of leukocy
with the anti-Mer antibody. The data are from a group of normal healthy in
of Mer on the CD14int population and the CD14++ monocytes was examincharacterized subpopulations of monocytes present in
peripheral blood [27]. We observed a subset of cells ex-
pressing intermediate levels of CD14 (14int in Figure 1A),
and this population had higher levels of Mer compared
with the monocytes expressing high levels of CD14 and
myeloid dendritic cells. Because CD14 intermediate
monocytes expressing CD16 are a distinct subset of
monocytes with potentially important patrolling function
in the vasculature [28], we wished to demonstrate that
the 14int population were monocytes and to look at Mer
expression on the monocyte subsets. Therefore, we used
another antibody panel on a second group of subjects
(Group 2), by using antibodies specific for CD14, CD16,
and MHC II to identify monocyte subsets (Figure 2).
Interestingly, we found that within the monocyte sub-
sets, Mer was expressed at highest levels on the popula-
tion of monocytes expressing CD16 and high levels of
CD14 (CD14++CD16+) monocytes [27], somewhat lower
levels on the nonclassic monocytes expressing CD16,
CD14intCD16+ population, and at lowest levels in the
classic monocytes not expressing CD16 but expressing
high levels of CD14 (CD14++CD16−) (Figure 2B, C). The
classic monocytes comprise the majority of monocytes
in the circulation.
We also examined the expression of Mer on dendritic
cells in the second set of subjects by using another anti-
body panel. Dendritic cells were identified as illustrated
in Figure 3A. CD1c+ dendritic cells comprise the largest
population of myeloid dendritic cells in normal blood
[27]. These cells were identified in the HLADR+CD3−heral blood of normal individuals. (A) Gating strategy for
te subsets. MFI represents the mean fluorescence intensity obtained
dividuals (n = 14). (C) Mer expression varies over time. The expression
ed in two normal individuals at different time points.
Figure 2 Expression of Mer on monocyte subpopulations from the peripheral blood of normal individuals. (A) Gating strategy for the
identification of monocyte subsets. (B) Expression of Mer on the surface of monocyte subpopulations from the peripheral blood of two
representative normal individuals. (C) Mean expression of Mer on monocyte subsets of normal individuals (n = 20).
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using CD19. Plasmacytoid dendritic cells were identified
as HLADR+CD3−CD123hi cells. We observed Mer ex-
pression on the surface of both CD1c+ myeloid DCs
(mDCs) and on the surface of plasmacytoid dendritic
cells (pDCs). Levels of Mer were higher on the surface
of CD1c+ mDCs than on the surface of pDCs (Figure 3B
through D).
Expression of TAMR on peripheral blood mononuclear
cells from SLE patients
When we compared SLE patients with normal controls,
we found no difference in expression of Mer on CD14+
monocyte populations in either of the two groups of
subjects we tested (Figure 4A, B). Mer expression in
monocytes from lupus patient blood followed the same pat-
tern as in monocytes from healthy individuals, with highest
expression in the CD14++CD16+ populations and lowest in
the CD14++CD16− populations. In CD14++CD16+ mono-
cytes, Mer expression levels were lower in SLE com-
pared with normal, although full statistical significance
was not reached (Figure 4B). A statistically significant
increase in the levels of Mer expression compared with
normal subjects was observed on SLE dendritic cells.
Among DCs, a significant increase in the levels of Mer
expression was found in both pDCs and in CD1c+ mye-
loid DCs from lupus patients compared with healthy
control subjects (Figure 4C). The lupus myeloid DC dataincluded one high-expression outlier; however, even if
that data point were excluded from the analysis, the dif-
ference remained significant. Because the function of
Mer expressed on the surface of peripheral blood leuko-
cytes can be suppressed by the presence of sMer in the
blood [29], we examined the levels of sMer in plasma
samples from the normal and lupus patients. In agree-
ment with earlier studies [23,25], increased levels of
sMer were present in the blood of lupus patients com-
pared with normal healthy individuals (Figure 4D).
Mer is generally not thought to be expressed on
lymphocytes, and we found only minimal levels in our
patients, yet clearly above background. When T-cell ex-
pression was examined more closely, an increase in Mer
expression was found on CD4+ but not CD4− T cells in
lupus patients compared with the normal control sub-
jects (Additional file 1: Figure S2A). The significance of
this increase is uncertain.
Because our control group was not gender-matched to
the predominantly female SLE patient group, we
wondered whether male–female differences alone might
influence Mer levels. Accordingly, we narrowed the con-
trol group to include only female subjects. Although no
significant differences were found between Mer expres-
sion on monocyte subsets between lupus patients and
normal healthy individuals (Additional file 1: Figure
S3A), the increases in Mer expression on CD1c+ and
pDCs in lupus patients was preserved (Additional file 1:
Figure 3 Expression of Mer on dendritic cell populations from the peripheral blood of normal individuals. (A) Gating strategy for the
identification of dendritic cells subsets. (B) Expression of Mer on the surface of CD1c+ myeloid dendritic cells subpopulations from the peripheral
blood of a representative normal individual. (C) Expression of Mer on the surface of pDCs on myeloid dendritic cells subpopulations from the
peripheral blood of a representative normal individual. (D) Expression of Mer on dendritic subsets of normal individuals (n = 15). Horizontal bars
represent mean values.
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on the monocytes and DC from female and male sub-
jects within our control group. We did observe some-
what higher levels of Mer on the CD14++CD16+
monocyte subset in normal females compared with the
SLE group (Additional file 1: Figure S3C). Also in both
CD1c+ myeloid DC and pDC populations, Mer expres-
sion was higher in healthy men compared with healthy
women (Additional file 1: Figure S3D), yet the differ-
ences failed to reach statistical significance. Thus, it is
unlikely that sex differences accounted for our findings.
The possibility that racial differences were important,
however, is real and will require further investigation.
Because type I interferon can activate expression of
TAMR in vitro [9,11], and because interferon levels are
related to active disease in SLE patients [30], we hypoth-
esized that the levels of Mer might be influenced by the
levels of interferon in the blood of patients with SLE.
We tested the plasma of lupus patients from the same
blood samples used for the flow-cytometry test for Mer
expression. We used an interferon type I reporter assaywith the interferon-stimulated response element that is
activated by the interferon-stimulated gene factor 3
complex pathway of activation by IFN-I. We observed
IFN-I activity levels above background in many of the
lupus patient samples, yet in none of the normal controls
(Figure 5A). Interferon activity was positively associated
with Mer expression on CD14intCD16+ and CD1c+ mye-
loid dendritic cells (Figure 5B and C). Interestingly, inter-
feron activity levels were also negatively associated with
the proportion of the CD14intCD16+ monocyte subset and
the CD1c+ DCs and positively with the proportion of the
CD14++CD16+ monocyte subset (Figure 5D through F).
We also examined associations between levels of Mer
expression on the monocyte subsets and myeloid DC
with various clinical parameters. Mer expression did not
correlate with organ involvement, autoantibody, age, or
SLEDAI score. Interestingly, the levels of Mer on the
monocyte subsets in SLE patients who were being
treated with prednisone were positively correlated with
dose (Figure 6A). No significant difference was found in
the levels of Mer expression on monocytes from those
Figure 4 Expression of Mer in blood from normal individuals and patients with SLE. (A) Results from the first group of individuals for
monocytes. Horizontal bars indicate means. (B) Results from the second group of individuals for monocytes. Horizontal bars indicate means.
(C) Results from the second group for dendritic cell populations. Horizontal bars indicate medians, and * indicates statistical significance
(Mann–Whitney, P < 0.05). (D) Quantification of soluble Mer in the plasma of lupus and healthy individuals. Horizontal bars represent median
values. ***Statistical significance (Mann–Whitney, P < 0.001).
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receiving prednisone or normal healthy control subjects
(Figure 6B). However, CD1c+ myeloid dendritic cells in
patients receiving prednisone had higher levels of Mer
expression than did those in patients not receiving pred-
nisone (Figure 6C). Levels of Mer expression on CD1c+
DC appeared to be higher in patients not treated with
prednisone compared with normal healthy individuals;
however, this difference just failed to reach significance
(P = 0.0729)
Of note, the Mer levels on the three monocyte subsets
were highly correlated with each other and also with
Mer levels on the CD1c+ DC population (Figure 7). The
levels of Mer expression on the CD14intCD16+ subpopu-
lation were negatively correlated with their proportion,
with the proportion of the CD14++CD16+ subpopulation,
and also with the proportion of both CD1c+ mDC and
pDCs found in the blood (Figure 8). These data suggest
that Mer expression on monocytes and DCs is related to
their total numbers and thus to the magnitude of on-
going inflammation.
We also found a strong correlation between the levels
of Mer on the CD1c+ mDCs with the proportion of
pDCs in the blood (Figure 9A). Additionally, the propor-
tions of both CD1c+ DCs and the pDCs were reduced in
the SLE group compared with the normal healthy con-
trol group (Additional file 1: Figure S4).We did not find a correlation between the levels of
sMer with membrane-bound Mer on the surface of any
cell type examined. However, sMer levels were negatively
correlated with the numbers of neutrophils in the blood
of lupus patients (Figure 9B).
Because prednisone treatment influences the levels of
Mer on peripheral blood monocytes and dendritic cells,
we looked at the subgroup of patients not receiving
prednisone (Additional file 1: Figure S5). Notwithstand-
ing the lower number of data points, we observed add-
itional positive correlates of IFN-I activity with Mer
expression on CD14++CD16+ monocyte populations and
also notably with sMer. Increased strength of correlation
(Spearman r) of IFN-I activity was noted, positively to
the expression of Mer on the CD14intCD16+ subgroup
of monocytes, and negatively to the proportion of this
monocyte subpopulation present in peripheral blood. An
increased strength of positive correlation of IFN-I activ-
ity also was noted with the proportion of CD14++CD16+
monocyte subpopulation,
As expected, Tyro3 was generally expressed at low
levels in leukocyte subsets in peripheral blood. However,
in some normal individuals and some SLE patients,
Tyro3 was expressed above background levels in the
CD14int cells and B-cell populations (Additional file 1:
Figure S2A). Surprisingly, a small but significant increase
in Tyro3 expression was present on CD4+ T cells in
Figure 5 Expression of Mer on monocytes and myeloid dendritic cells in patients with SLE correlates with IFN-I activity. Interferon
activity influences the proportion of monocytes and myeloid dendritic cells in blood. (A) IFN-I activity in plasmas from normal individuals and SLE
patients. The optical density units obtained for plasma-induced alkaline phosphatase activity in plasmas are shown. Mer levels on (B) CD14intCD16+
monocyte and (C) CD14++CD16− and CD1c+ DC subsets positively correlate with IFN-I activity. The proportions of (D) CD14intCD16+ monocytes,
(E) CD14++CD16− monocytes, and (F) CD1c+ myeloid dendritic cell subsets negatively correlate with IFN-I activity. Spearman rank correlation
was used to determine significance. Values for Spearman r and P values are given for the different correlates.
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sociated with the expression of Mer in the CD4+ T lym-
phocytes of lupus patients (Figure 9C).
Discussion
The present findings establish that Mer is expressed pri-
marily on monocytes and dendritic cells in humans.
Contrary to our expectations, we did not find reduced
Mer expression on blood mononuclear cells from SLE
patients. In contrast, the expression of Mer in certain
monocytes and myeloid dendritic cells was increased,
and this correlated with type I interferon levels. The cell
distribution of human Mer expression parallels our find-
ings of Mer expression in the mouse [31,32]. Normal
human monocytes expressed significant levels of Mer
overall, and expression was higher on CD16+ monocytes,
especially the CD14++CD16+ subset of monocytes, with
lower levels on the CD14++CD16− subset. Mer expres-
sion is greatly increased in human macrophages matured
in vitro [33], and specifically those differentiated alongthe M2 lineage [34]. The relatively low levels of Mer ob-
served in human peripheral blood monocytes are there-
fore probably reflective of their relatively undifferentiated
state.
Compelling evidence suggests that the three monocyte
populations represent a continuous line of development in
the circulation, with the CD14++CD16+ population repre-
senting a transitional phase between the least-advanced
classic CD14++CD16− monocytes and the most-mature
CD14intCD16+ monocytes [35], with some characteristics
of tissue macrophages [36].
However, functional differences exist between monocytes
segregated into the three populations. The CD14++CD16+
subset respond well to LPS, producing more TNF-α
and IL-1β than the other monocyte subsets [28], but
they also produce significant amounts of the antiin-
flammatory cytokine IL-10 [37]. Good evidence indi-
cates that the CD14++CD16+ monocytes can efficiently
activate T cells, as they express high levels of MHC
class II compared with the other subsets [38], and
Figure 6 Prednisone dose correlates with Mer expression on all
three monocyte subsets in patients with SLE receiving
prednisone; and prednisone treatment increases Mer expression
on myeloid dendritic cells. (A) Spearman rank correlation was used
to determine the significance of correlation between Mer levels in
patients receiving prednisone and dose levels of the prednisone.
Values for Spearman r and P value are given for the different correlates
in the Table. (B) Mer levels on monocytes were compared between
normal healthy controls and SLE patients not treated and treated with
prednisone. (C) Mer levels on dendritic cells were compared between
normal healthy controls and SLE patients not treated and treated with
prednisone. Significance was determined by using the Mann-Whitney
rank correlation test. Horizontal bars indicate the median values for the
groups. *P < 0.05; **P < 0.001.
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induced T-cell response. Therefore, the higher expression
of Mer on these cells suggests that it can play an import-
ant role in regulating apoptotic cell phagocytosis and any
ensuing T-cell response. Based on the higher levels of Mer
expression on CD14++CD16+ monocytes, a role for Mer
may exist in other diseases. The CD14++CD16+ subset are
expanded in patients with rheumatoid arthritis [39]. In-
creased numbers of the population predict the risk of car-
diovascular disease in patients with chronic kidney disease
[40], patients receiving hemodialysis [41], and patients se-
lected for coronary angiography [42]. However, the ex-
pression profile of Mer in these conditions is not known.
In contrast to the CD14++CD16+ subset, the CD14intCD16+
population of monocytes respond poorly to LPS but
have an enhanced reaction to viruses and nucleic acids
[28]. The human CD14intCD16+ monocyte subset also
have a unique patrolling function in the vasculature, as
demonstrated by their ability to ”crawl” on the endo-
thelium of mouse blood vessels, [28]. It is tempting,
therefore, to propose a role in vascular endothelial re-
pair for these specialized monocytes because of the po-
tential role of Mer in the recognition and removal of
damaged endothelial and other component cells of the
vasculature that express phosphatidyl serine on their
surfaces.
The increased expression of Mer in the CD16+ subsets
of monocytes is consistent with a role for Mer in the
phagocytosis of apoptotic cells, because among mono-
cytes, the CD16+ monocytes preferentially phagocytose
apoptotic cells [34]. The relatively high expression of
Mer in the CD16+ cell subsets is also consistent with a
role for Mer in the observed inhibition of TNF-α and
IL-1β production in CD16+ monocytes by apoptotic
neutrophils [43].
Our finding that circulating human myeloid DCs ex-
press Mer, parallels the expression of Mer on fresh
splenic DCs in mice. Although Mer is not required for
phagocytosis of apoptotic cells in mouse dendritic cells
[31], with Axl and Tyro3 being more important for the
Figure 7 Levels of Mer on CD14intCD16+ monocytes positively correlate with the levels of Mer in the other monocyte subgroups and
on CD1c+ myeloid DCs. Spearman rank correlation was used to determine significance. Values for Spearman r and P value are presented for the
different subsets in the table.
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http://arthritis-research.com/content/16/2/R76phagocytosis of apoptotic cells by mouse splenic and
bone marrow-derived dendritic cells [12], Mer functions
as an important regulator of DC activation in mice
[7,44]. The loss of Mer in in vitro-generated mouse den-
dritic cells led to a lack of the regulation of NF-κBFigure 8 Levels of Mer on CD14intCD16+ monocytes are negatively co
proportion of CD1c+ dendritic cells, and the proportion of pDCs in bl
Values for Spearman r and P values are presented for the different correlatiactivation by apoptotic cells. In a mouse model of auto-
immune diabetes, loss of Mer was associated with in-
creased numbers of pancreatic DCs and an increased
ability of DCs to stimulate islet-specific T cells [45].
Therefore, a lack of Mer-dependent DC regulation couldrrelated with the proportion of CD14intCD16+ monocytes, the
ood. Spearman rank correlation was used to determine significance.
ons in the table.
Figure 9 Correlates of Mer levels in peripheral blood of lupus patients. (A) Mer levels on CD1c+ dendritic cells are negatively correlated
with the proportion of pDCs in lupus blood. (B) sMer levels in blood are negatively correlated with the numbers of neutrophils in the blood of
lupus patients. (C) Levels of Mer on the surface of CD4+ T cells are positively correlated with levels of Tyro 3.
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http://arthritis-research.com/content/16/2/R76lead to an increase in T-cell autoreactivity and increased
autoimmune disease.
Mer is expressed in splenic NK and NKT cells in mice,
and has been shown to have functional significance in
the activation of NKT cells [31]. The present data indi-
cate that expression on circulating human NK cells is
negligible. We did not find enough NKT cells in the
PBMC fraction to make any conclusion regarding Mer
expression. Other subsets of leukocytes, including CD8+
T cells and B cells, also had negligible levels of Mer ex-
pression, suggesting that Mer has no functional role in
these cells under normal healthy circumstances.
We observed an increase in expression of Mer on
CD1c+ mDCs and also in plasmacytoid DCs in lupus
blood. These data suggest that no defect in Mer expres-
sion exists in lupus. The increase in Mer expression in
DCs may reflect a response to an inflammatory environ-
ment in SLE akin to the activation of TAMR in response
to TLR activation in monocytes [46]. The association of
increased Mer expression with inflammation is also a
feature of alveolar macrophages in the chronic lung in-
flammation seen in smokers [13] and also in monocytes
in patients with septic shock [14]. In vitro experiments
with human monocyte-derived DCs demonstrate that
Axl is induced by type I interferon [9,11]. Analogously,
therefore, Mer expression may also be a response to the
type I interferon signature that characterizes lupus
[47,48]. Thus increased Mer expression on DCs may
represent a marker of IFN-I activity in lupus patients.
This hypothesis is strongly supported by our results
demonstrating a positive association between IFN-I ac-
tivity and Mer levels on monocyte subsets and myeloid
dendritic cells.
A notable negative correlation was noted between Mer
expression on the CD14intCD16+ subset of monocytes
with the proportions of the same CD14intCD16+ subset
of monocytes, the CD1c+ DC, and the pDC populations.
This is consistent either with a selective killing of thesecell subsets, or with an increased migration of the CD16+
monocytes into the tissues. The former hypothesis sug-
gests a lack of Mer-expressing phagocytes in certain lupus
patients, which could be involved in the reported defect in
the ability of macrophages from lupus patients to phago-
cytose apoptotic cells [17-20]. The latter hypothesis is sup-
ported by the established behavior of the CD14intCD16+
subset of these cells that is able to patrol the surface of the
vascular endothelium and is more adherent than the
CD14++ subpopulation of CD16+ and the classic CD16−
monocytes [28] and hence is more likely to migrate from
the vasculature into tissues.
Similarly, studies focusing on the total CD16+ mono-
cyte population have demonstrated the increased adher-
ent and transmigratory ability of these monocytes. Thus,
the monocyte subsets expressing most Mer are more in-
clined to adhere to and transmigrate through the vascu-
lar endothelium [49-51], whereupon they may then
partake in the phagocytosis of apoptotic cells in tissues.
Mer expressions on all three monocyte subsets are posi-
tively associated with each other and with the Mer
expressed on myeloid DC, arguing for a global regula-
tion of Mer expression on monocyte and myeloid den-
dritic cells.
Remarkably, we also found an inverse correlation be-
tween the expression of Mer on the CD14intCD16+
monocytes and the proportions of both the CD1c+ mye-
loid and the plasmacytoid dendritic cells. Additionally,
we found that the proportions of both pDCs and CD1c+
myeloid dendritic cells were decreased in the SLE pa-
tient group compared with normal healthy subjects. The
reduction in the numbers of pDCs has been reported
[52] and may reflect recruitment from the peripheral
blood to diseased tissues during disease episodes [53,54].
A role may exist for TAMR signaling in regulating
autoimmunity via IFN-I signaling. In in vitro cultures of
mouse bone marrow-derived dendritic cells, IFN-α in-
duced Axl expression that downregulated inflammatory.
Hilliard et al. Arthritis Research & Therapy 2014, 16:R76 Page 12 of 15
http://arthritis-research.com/content/16/2/R76Most of the homeostatic phagocytosis that takes place
in an organism most probably occurs in solid tissues ra-
ther than in peripheral blood. It is likely that the expres-
sion of Mer is increased substantially in tissue-resident
macrophages and hence that these macrophages are
more efficient at removing apoptotic cells compared
with peripheral blood monocytes. Although we did not
address the question of how much Mer is necessary to
evoke a functional phagocytic or regulatory response, it
seems that the differences in Mer levels between the
CD16+ monocytes and the CD16− monocytes contribute
to the increased efficiency of the CD16+ monocytes at
ingesting apoptotic neutrophils [34].
It is also possible that the increased expression of Mer
on DCs in lupus patients may reflect a defect in Mer
function in these cells, which could activate a compensa-
tory pathway to upregulate Mer expression. Pertinent to
this is our observation [55], and those of others [23,25],
that increased levels of sMer are found in the blood of
lupus patients compared with healthy control subjects.
Increased levels of sAxl and sTyro3 have also been found
in lupus patient blood [22,23], and all three soluble
TAMRs can compete for the TAMR ligands Gas6 and
protein S to block Mer function. This, through competi-
tion for ligand, can lead to a suppression of membrane-
bound Mer activation [29] and a decreased function of
Mer in lupus.
In mouse models of lung disease, prevention of the pro-
teolytic cleavage of Mer led to beneficial Mer-dependent
pro-phagocytic and anti-inflammatory responses [56,57].
These results in mice suggest that increasing membrane-
bound Mer activation may also have a beneficial effect in
SLE.
Glucocorticoids induce a Mer/protein S-dependent mech-
anism of apoptotic cell removal in human monocyte-
derived macrophages [58]. In keeping with this in vitro
observation, Mer expression on monocytes of our SLE pa-
tients receiving prednisone correlated strongly with the
dose of corticosteroid (Figure 6A). Unexpectedly, no over-
all difference was noted in Mer expression on the mono-
cytes of those lupus patients taking prednisone compared
with those not given prednisone. Patients not taking pred-
nisone at all may differ clinically from those patients who
merited prednisone, even small doses. This may be
reflected in the normal or slightly elevated monocyte Mer
expression in the presumably inactive patients not taking
corticosteroids. Yet it was clear that prednisone increased
Mer expression in a dose-dependent fashion in those pa-
tients sick enough to merit prednisone treatment.
We also found that prednisone-treated lupus patients
had increased Mer expression on their CD1c+ myeloid
DCs. The apparent relation between steroid dose and
monocyte and DC Mer expression parallels in vitro ob-
servations that glucocorticoids prominently induce Mer,together with a broader upregulation of proteins in-
volved in the antiinflammatory phagocytic pathway spe-
cific for apoptotic cells [33,34,59]. The in vivo induction
of Mer on monocytes, and especially dendritic cells,
therefore may constitute an important part of the mech-
anism of immunosuppression induced by prednisone
treatment.
In patients not being treated with prednisone, we
found an association of sMer in blood with IFN-I activ-
ity levels. Because no direct upregulatory effect of type I
IFNs was found on sMer release from in vitro cultures
of monocytes [55], this association may depend on other
disease-related factors. For example, this could reflect an
increased activity in lupus blood, of specific proteases,
such as ADAM10 and ADAM17 (TNF-α-converting en-
zyme, TACE), which are capable of enzymatically con-
verting membrane-bound Mer to soluble Mer. Our
observations also suggest that a strong homeostatic
mechanism may exist for Mer expression on the surface
of monocytes and dendritic cells in peripheral blood.
We found that Tyro3 and Mer are expressed on CD4+
T cells in some individuals with lupus. An increased Mer
and Tyro3 expression on CD4+ cells was noted in lupus
patients compared with normal control subjects. Mer
levels correlated with Tyro3 levels on the surface of CD4+
T cells in lupus patients. The significance of this is unclear;
however, it may be of interest because Mer has a prosurvi-
val effect in the human Jurkat T-cell lymphoma [60] and
also in other lymphomas overexpressing Mer [61], and
therefore, it could potentially have a role in prolonging
survival of autoreactive T cells in lupus. Clearly the role of
TAMR in T-cell activation in inflammatory diseases de-
serves further study.
It will be interesting to look at other rheumatic dis-
eases to see whether a similar regulation of Mer expres-
sion exists, and whether the Mer-expression pattern is
unique to lupus.
Finally, although it is reasonable to believe that the ex-
pression of TAMR on blood leukocytes reflects the ex-
pression of Mer on immune cells in solid tissues, our
study does not preclude the possibility that Mer expres-
sion is deficient in involved organs.
Conclusions
Our data show that no defect in Mer expression is
present in SLE patients. In contrast, the increased levels
of Mer on the surface of myeloid and plasmacytoid DCs
may reflect the enhanced IFN-I inflammatory environ-
ment in SLE, and may also represent a compensatory re-
sponse to reinstate immune tolerance and effect an
antiinflammatory state. Also, because corticosteroid ther-
apy enhances Mer expression on circulating monocytes
and dendritic cells, this therapy may exert beneficial ef-
fects by enhancing phagocytic capacity for apoptotic
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in SLE patients.Additional file
Additional file 1: Figure S1. Mer and Tyro3 expression in cell lines.
(A) Cell lines U937, phorbol myristate acetate-stimulated THP-1, and
Jurkat stained with monoclonal anti-Mer-PE. (B) K562 cells stained with
monoclonal anti-Tyro3-PE Figure S2. Comparison of Mer and Tyro3
expression in leukocyte populations in the blood of normal healthy
subjects and SLE patients. (A) Expression of Mer on lymphocyte populations
in normal individuals and patients with SLE. (B) Expression of Tyro3 on
leukocyte subpopulations from normal individuals and patients with
SLE. Figure S3. Comparison of Mer expression in normal females with
SLE patients and effect of gender on expression of Mer. (A) Mer
expression levels on monocytes from normal females and patients with
SLE. (B) Mer-expression levels on dendritic cells from normal females
and patients with SLE. (C) Mer expression levels on monocytes from
normal female and male subjects. (D) Mer-expression levels on
dendritic cells from normal female and male subjects. Figure S4.
Comparison of monocyte and dendritic cells proportions in normal
healthy subjects and SLE patients. (A) Monocyte population proportions
of peripheral blood mononuclear cells are similar between SLE and
normal healthy subjects. The bars represent the mean values. (B) CD1c+
and plasmacytoid dendritic cell proportions of peripheral blood
mononuclear cells are reduced in patients with SLE compared with
normal control subjects. Figure S5. Mer expression on monocytes, sMer in
blood, and proportions of monocyte subsets correlate with IFN-I activity in
SLE patients that do not receive prednisone. Mer levels on monocyte
subsets. (A) CD14++CD16+, (B) CD14intCD16+, and (C) CD14++CD16-
and sMer levels in (D) plasma, positively correlate with interferon
activity. Proportions of monocyte subsets correlate with IFN-I activity,
negatively for (E) CD14intCD16+ monocytes, and positively for (F) CD14++CD16-
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